2.44

6.15% -0.16

After Hours: 2.39 -0.05 -2.05%

Entera Bio Ltd (ENTX)

Overview News Price History Option Chain Financials Discussions Forecast

Entera Bio Ltd stock is currently priced at $2.44, with a 24-hour trading volume of 82,311. It has seen a -6.15% decreased in the last 24 hours and a +9.91% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.61 pivot point. If it approaches the $2.30 support level, significant changes may occur.

Previous Close:

$2.60

Open:

$2.6

24h Volume:

82,311

Market Cap:

$87.32M

Revenue:

$134.00K

Net Income/Loss:

$-9.93M

P/E Ratio:

-6.5946

EPS:

-0.37

Net Cash Flow:

$-6.72M

1W Performance:

-0.81%

1M Performance:

+9.91%

6M Performance:

+234.25%

1Y Performance:

+146.46%

1D Range:

$2.354

$2.60

52W Range:

$0.52

$3.35

Entera Bio Ltd Stock (ENTX) Company Profile

Name

Entera Bio Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 2 532 7151

Address

Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

ENTX's Discussions on Twitter

Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-22-21	Initiated	Aegis Capital	Buy

Entera Bio Ltd Stock (ENTX) Latest News

A Guide To The Risks Of Investing In Entera Bio Ltd (ENTX) – Knox Daily - Knox Daily

Knox Daily

HC Wainwright Analysts Lower Earnings Estimates for Entera Bio Ltd. (NASDAQ:ENTX) - MarketBeat

MarketBeat

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - Yahoo Finance

Yahoo Finance

Entera Bio Ltd Stock (ENTX) Financials Data

Entera Bio Ltd (ENTX) Revenue 2024

ENTX reported a revenue (TTM) of $134.00 thousand for the quarter ending December 31, 2022, a -76.53% decline year-over-year.

Entera Bio Ltd (ENTX) Net Income 2024

ENTX net income (TTM) was -$9.93 million for the quarter ending September 30, 2023, a +29.34% increase year-over-year.

Entera Bio Ltd (ENTX) Cash Flow 2024

ENTX recorded a free cash flow (TTM) of -$6.72 million for the quarter ending September 30, 2023, a +48.53% increase year-over-year.

Entera Bio Ltd (ENTX) Earnings per Share 2024

ENTX earnings per share (TTM) was -$0.34 for the quarter ending September 30, 2023, a +32.00% growth year-over-year.

Entera Bio Ltd Stock (ENTX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Taitel Haya	Director	Jan 10 '24	Buy	0.77	7,615	5,864	25,615
LIEBERMAN GERALD M	Director	Dec 22 '23	Buy	0.71	23,952	17,006	226,961
Toledano Miranda Jayne	Chief Executive Officer	Dec 22 '23	Buy	0.71	23,952	17,006	110,752
Taitel Haya	Director	Aug 22 '23	Buy	0.62	18,000	11,216	18,000
Ellis Sean	Director	Aug 21 '23	Buy	0.60	40,000	24,000	102,100
LIEBERMAN GERALD M	Director	Aug 21 '23	Buy	0.59	20,000	11,784	214,209

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.